Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals, a biotechnology company, has appointed Bruce Peacock and Steven Burakoff to its board of directors, following the company's recent acquisition of Pharmacopeia.
Subscribe to our email newsletter
Mr Peacock is president and CEO of Alba Therapeutics, and has also been a venture partner with SV Life Sciences since May 2006. Mr Peacock currently serves as a member of the board of directors of NeurogesX, a biotechnology company, as well as several private biotechnology companies.
Dr Burakoff is a director of the Tisch Cancer Institute at the Mount Sinai Medical Center, where he also serves as professor of medicine and professor of oncological sciences. Dr Burakoff has graduated from Lehigh University with a bachelor of science degree, received his master’s degree from Queens College, and his MD from Albany Medical College.
John Kozarich, chairman of the board, said: “We are delighted to have Bruce Peacock and Steven Burakoff join our board. Together, they have broad and diverse backgrounds with solid scientific and medical credentials, as well as extensive biotechnology industry knowledge. We look forward to the expertise and perspective they will bring to Ligand’s board.”